New Delhi: Indian government para third stimulus package Rs. 900 crore Mission COVID Suraksha –Indian COVID-19 Vaccine Development Mission nimete khobor dishe.
Etu grant toh the Department of Biotechnology (DBT) Research & Development of Indian COVID19 vaccines nimete dibo.
COVID19 Vaccine development Mission end-to-end focus preclinical development te thakikena through clinical development and manufacturing and regulatory facilitation deployment, nimete etu para sob thaka aro funded resources accelerated product development nimete.
Etu fund laga important objective toh pre-clinical and clinical development; licensure of COVID-19 vaccine candidates laga uthabole nimete ase etu toh etia clinical stages te ase nohoile toh tayar kuri ase clinical stage development te ghussibole nimete aro clinical trial sites khan te punchibole nimete.
Etu fund laga dusra objective khan te etia thaka immunoassay laboratories khan kara kuribole nimete ase central laboratories aro animal studies nimete suitable facilities,production facilities aro dusra testing facilities khan ase COVID-19 vaccine development te support nimete.
Etu laga dusra important objective toh common harmonized protocols, training, data management systems, regulatory submissions, internal and external quality management systems aro accreditations te support kuribole nimete ase.
Capabilities process development, cell line development aro manufacturing GMP batches animal toxicology studies nimete aro clinical trials nimete etu mission bithor te support kuribo.
Ekta key element toh suitable Target Product Profile bonabole nimete ase etu para vaccines khan toh shuru kuribole mission para preferred characteristics applicable India nimete thakibo.
department of biotechnology para loikena aro dedicated Mission Implementation Unit at Biotechnology Industry Research Assistance Council (BIRAC), para chulaikena etia thaka activities khan National Bio Pharma Mission (NBM) and Ind-CEPI Mission khan ke complementary strengths dibo etu mission nimete.
COVID Suraksha Mission Phase-I te Rs. 900 crore toh 12 moina nimete dikena ase.komti hoilebi sob milaikena 10 nishena vaccine candidates khan department of biotechnology para support kurishe etia tak academia aro industry nimete.
Etia tak human trials te paanchta vaccine candidates ase etu te Russian vaccine Sputnik-V ase etu te komti hoilebi aro bi tinta nishena advance stages te preclinical ase etu bi human trial toh joldi punchibole nimete.
Add Comment